P. A. Clarke

R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers

This study shows APOBEC3B edits R-loops at ER enhancers, leading to DSBs that contribute to genomic instability in breast cancer.

Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors

The paper shows that loss of Spindly increases sensitivity of EML4-ALK v3 NSCLC cells to HSP90 inhibitors, but not v1 cells.

Native size exclusion chromatography-based mass spectrometry (SEC-MS) identifies novel components of the Heat Shock Protein 90-dependent proteome

This study uses SEC-MS to analyze HSP90 inhibitor effects on protein complexes, identifying both known and novel components of the HSP90-dependent proteome.

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

This paper identifies PF-477736 as a selective cytotoxic compound for LIMD1-deficient NSCLC cells and xenograft models, offering a potential targeted therapy for this understudied cancer subtype.

Evolution of kinase polypharmacology across HSP90 drug discovery

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma.

This study shows that PDE5 inhibition reduces CAF tumor-promoting effects and enhances chemotherapy efficacy in EAC models.

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

This study shows that MET/FAK signaling can activate CDK2 independently of CDK4/6, leading to cell division, and suggests targeting MET/FAK could enhance CDK4/6 inhibitor therapies.